The Effect of Mindfulness-Based Breathing Exercises on Dyspnea, Symptom Control, and Quality of Life in Lung Cancer Patients Undergoing Chemotherapy

April 9, 2026 updated by: Gülcan Bahçecioğlu Turan, Firat University

The Effect of Mindfulness-Based Breathing Exercises in Lung Cancer Patients Undergoing Chemotherapy

This research is designed to determine the effect of mindfulness-based breathing exercises on dyspnea, symptom control, and quality of life in lung cancer patients undergoing chemotherapy. Lung cancer is a disease with a high mortality rate and a heavy symptom burden, and symptoms such as dyspnea, fatigue, pain, anxiety, and sleep problems are frequently observed during chemotherapy. Dyspnea, in particular, is one of the main symptoms that has both physical and emotional dimensions and significantly negatively affects patients' daily living activities, adherence to treatment, and quality of life. Therefore, integrating non-pharmacological and complementary nursing interventions into the care process in addition to pharmacological approaches is important. Mindfulness-based breathing exercises are a structured application that aims to regulate the respiratory rhythm, increase relaxation, and reduce symptom perception by enabling the individual to focus on their breath and bodily sensations without judgment. The research will be conducted using a pre-test-post-test control group experimental design. The study will be carried out with lung cancer patients receiving chemotherapy at Gazi Yaşargil Training and Research Hospital between April 2026 and September 2026. The study sample will consist of a total of 60 patients (30 experimental, 30 control) who meet the inclusion criteria and voluntarily agree to participate. Randomization will be used to determine the groups. Patients in the intervention group will receive a mindfulness-based breathing exercise program for eight weeks. The first four weeks will consist of 20-30 minute face-to-face individual training sessions once a week, followed by four weeks of 15-20 minute exercises at home twice a week. The control group will receive no intervention other than routine care. Data will be collected before and eight weeks after the intervention using a Personal Information Form, the Edmonton Symptom Assessment Scale, the EORTC QLQ-C30 Quality of Life Scale, and the Dyspnea-12 TR Scale. Frequency, percentage, mean, and standard deviation will be calculated for data analysis; chi-square test, independent samples t-test, and dependent samples t-test will be used for intergroup comparisons. This study is expected to provide evidence-based contributions to nursing care by demonstrating the effectiveness of mindfulness-based breathing exercises in reducing dyspnea and symptom burden and improving quality of life in lung cancer patients undergoing chemotherapy.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Center
      • Elâzığ, Center, Turkey (Türkiye), 25240
        • Fırat university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Being over 18 years of age
  • Being able to communicate adequately
  • Not having a psychiatric problem
  • Those whose physical condition preventing them from exercising has been determined by a physician
  • Patients who have completed at least 4 courses

Exclusion Criteria:

  • Individuals with communication problems
  • Individuals with psychiatric problems
  • Patients who engage in any kind of exercise
  • Will not be included in Phase 4 studies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mindfulness-Based Breathing Exercises
The group where the application was made
Mindfulness-Based Breathing Exercises
No Intervention: Control group
The group where the application was not made

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Edmonton Symptom Assessment Scale:
Time Frame: 8 week
The Edmonton Symptom Assessment Scale was developed by Bruera et al. to assess .nine common symptoms in cancer patients (Çalışkan, Gürhan, and Tekgündüz, 2017). The scale includes nine symptoms: pain, fatigue, nausea, sadness, anxiety, insomnia, loss of appetite, malaise, and shortness of breath. In the Turkish validity and reliability study conducted by Sadırlı (2008), skin and nail changes, mouth sores, and numbness in the hands were added to the original scale. Each symptom is evaluated on a numerical scale from 0 to 10. A score of 0 indicates that the symptom is not experienced at all; a score of 10 indicates that the symptom is experienced at its most severe level. The basic principle of the scale is that the patient makes their own assessment. Patients are asked to indicate the number that they think best reflects the severity of the symptom they are experiencing."Higher scores on the Edmonton Symptom Assessment Scale indicate greater symptom severity."
8 week
EORTC QLQ-C 30 Quality of Life Scale
Time Frame: 8 week
The EORTC QLQ-C30 Quality of Life Scale was developed in 1987 by the European Organization for Cancer Treatment and Research (EORTC) to assess the quality of life of cancer patients and was later revised by Aaronson et al. (Jameson et al., 2018). The adaptation of the scale to the Turkish population and the validity-reliability study were carried out by Güzelant et al., and the Cronbach alpha coefficient was found to be 0.70.
8 week
DYSPNEA-12 TR SCALE
Time Frame: 8 week

The Dyspnea-12 scale was developed by Yorke et al. to assess both the physical and emotional dimensions of dyspnea symptoms and was published in 2011 (Yorke et al., 2011). Consisting of 12 items, the scale has a four-point Likert-type response system, with each item scored from 0 to "none", 1 to "mild", 2 to "moderate", and 3 to "severe".

The first seven items of the scale are aimed at evaluating the physical symptoms related to dyspnea. Through these items, physical symptoms such as difficulty breathing, insufficient air reaching the lungs, and increased effort required during breathing are investigated. The remaining five items of the scale evaluate the effects of shortness of breath on the individual's emotional state; focusing on emotional responses such as stress, irritability, depressive mood, general distress, and restlessness.Higher scores on the Dyspnea-12 indicate greater severity of breathlessness.

8 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

April 3, 2026

First Submitted That Met QC Criteria

April 3, 2026

First Posted (Actual)

April 9, 2026

Study Record Updates

Last Update Posted (Actual)

April 14, 2026

Last Update Submitted That Met QC Criteria

April 9, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

Clinical Trials on Mindfulness-Based Breathing Exercises

Subscribe